Cytokinetics EVP sells shares to cover RSU taxes

Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported a company‑compelled sale of 8,542 shares of Common Stock at $62.15 per share on March 17, 2026 to cover tax withholding from RSU vesting.

Rhea-AI Filing Summary

Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported a company‑compelled sale of 8,542 shares of Common Stock at $62.15 per share on March 17, 2026 to cover tax withholding from RSU vesting.

These sell‑to‑cover transactions were executed in two tranches and are tied to compensation, rather than discretionary trading. Following the sales, Callos directly holds 71,573 Cytokinetics shares, maintaining a substantial equity stake in the company.

Insider Trade Summary

Net Seller: 8,542 shares

Net Sell 2 txns

Insider Callos Andrew

Role EVP, Chief Commercial Officer

Sold 8,542 shs ($531K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,626	$62.15	$350K
Sale	Common Stock	2,916	$62.15	$181K

Holdings After Transaction: Common Stock — 71,573 shares (Direct)

Footnotes (2)

1. F1. Company compelled sell-to-cover transaction to satisfy tax withholding obligations attributable to RSU vesting.
2. F2. Company compelled sell-to-cover transaction to satisfy tax withholding obligations attributable to RSU vesting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cytokinetics (CYTK) report for Andrew Callos?

Cytokinetics reported that Andrew Callos executed company‑compelled sell‑to‑cover transactions totaling 8,542 shares. The sales were triggered by tax withholding requirements related to restricted stock unit vesting, rather than a discretionary decision to reduce his investment position.

At what price were Andrew Callos’s Cytokinetics (CYTK) shares sold?

The 8,542 Cytokinetics shares tied to Andrew Callos’s sell‑to‑cover transactions were sold at $62.15 per share. This uniform price applied to both tranches executed on March 17, 2026, as part of satisfying payroll tax withholding on vested RSUs.

How many Cytokinetics (CYTK) shares does Andrew Callos hold after the Form 4 transactions?

After the reported sell‑to‑cover transactions, Andrew Callos holds 71,573 shares of Cytokinetics Common Stock directly. This post‑transaction balance reflects his remaining equity stake following the company‑compelled sales to meet tax withholding obligations from RSU vesting.

Were the Cytokinetics (CYTK) insider sales by Andrew Callos discretionary?

The sales were not discretionary; they were described as company‑compelled sell‑to‑cover transactions. The purpose was to satisfy tax withholding obligations arising from restricted stock unit vesting, indicating a compensation‑related event rather than an elective reduction of his share ownership.

What type of security was involved in Andrew Callos’s Cytokinetics (CYTK) Form 4 filing?

The Form 4 filing for Andrew Callos involved Cytokinetics Common Stock. The transactions reflect open‑market sales executed to cover taxes on RSU vesting, and there were no derivative securities such as options or warrants reported as part of this particular filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 05:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Callos Andrew

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S(1)		5,626	D	$62.15	74,489	D
Common Stock	03/17/2026		S(2)		2,916	D	$62.15	71,573	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Company compelled sell-to-cover transaction to satisfy tax withholding obligations attributable to RSU vesting.

2. Company compelled sell-to-cover transaction to satisfy tax withholding obligations attributable to RSU vesting.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Callos	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)